Back
Halozyme Therapeutics Stock Predictions
Mode Mobile Could be Next in Line
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
57
HALO
Halozyme Therapeutics
Last Price:
$58.80
Seasonality Move:
8.07%
7 Day Trial
ALL ACCESS PASS
$
7
Top investors are buying this "unlisted" stock
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.Halozyme Therapeutics Stock Forecast
-
Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 26.8% based on the past 21 years of stock performance.
-
Halozyme Therapeutics has risen higher in 12 of those 21 years over the subsequent 52-week period, corresponding to a historical accuracy of 57.14%
-
Is Halozyme Therapeutics Stock Undervalued?The current Halozyme Therapeutics [HALO] share price is $58.82. The Score for HALO is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.
-
HALO is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
Will Halozyme Therapeutics Stock Go Up Next Year?
-
Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 26.8% based on the past 21 years of stock performance.
Halozyme Therapeutics Stock Rating
Buy
57
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics overpriced?
-
Halozyme Therapeutics has risen higher in 12 of those 21 years over the subsequent 52-week period, corresponding to a historical accuracy of 57.14%
Halozyme Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
halozyme.com
52-Week Data
52-Week High:
66.00
52-Week Low:
37.73
Prediction Charts
Market Cap:
7.2B
Price in USD:
58.82
Volume:
1.7M
Beta:
1.44
Technical Analysis
SMA50:
60.18
SMA100:
55.17
SMA200:
55.72
52-Wk Change:
53.26%
Stock Predictions
-
Is Halozyme Therapeutics stock public?Yes, Halozyme Therapeutics is a publicly traded company.
-
What is the Halozyme Therapeutics stock quote today?The Halozyme Therapeutics stock price is 58.82 USD today.
-
How to buy Halozyme Therapeutics stock online?You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Mar-28 | 64.35 | 63.84 | 64.35 | 62.72 |
| Mar-31 | 63.39 | 63.81 | 64.07 | 62.60 |
| Apr-1 | 64.06 | 61.87 | 64.17 | 61.43 |
| Apr-2 | 61.70 | 63.02 | 63.14 | 61.54 |
| Apr-3 | 62.07 | 61.92 | 63.14 | 61.23 |
| Apr-4 | 60.72 | 59.77 | 60.98 | 59.11 |
| Apr-7 | 57.50 | 59.35 | 61.82 | 56.38 |
| Apr-8 | 60.87 | 57.54 | 61.37 | 56.93 |
| Apr-9 | 56.11 | 60.65 | 61.44 | 55.71 |
| Apr-10 | 59.19 | 57.70 | 59.64 | 56.68 |
| Apr-11 | 57.87 | 60.22 | 60.88 | 57.40 |
| Apr-14 | 61.30 | 61.39 | 62.13 | 60.06 |
| Apr-15 | 61.55 | 61.28 | 62.14 | 60.81 |
| Apr-16 | 61.17 | 58.82 | 61.30 | 57.50 |
Halozyme Therapeutics Earnings
Halozyme Therapeutics Earnings Report: Per Share Halozyme Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.
Halozyme Therapeutics Forecast Revenue Growth
Halozyme Therapeutics Stock Analysis: Historical quarterly revenues per share for Halozyme Therapeutics and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $0.33 per share, an increase next quarter of $0.02 per share, an increase this year of $0.77 per share, and an increase next year of $1.51 per share.
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.